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The Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, 2 with an estimated prevalence of 6 to 10% in this population. 3 According to the Rotterdam criteria, PCOS is diagnosed in the presence of at least two of the three criteria: menstrual disorders or amenorrhea with chronic lack of ovulation, clinical and/or biochemical characteristics of hyperandrogenism and the presence of polycystic ovaries on ultrasonography after exclusion of other endocrine disorders. 4 Overall, SOP has been considered a reproductive disorder; however, it also represents a significantly increased risk for cardiometabolic disorders. 2 The impact on reproduction is predominant during the reproductive years, while cardiometabolic alterations become more important in the later stages of a woman's life. 2 Women with PCOS are at increased risk of obesity, arterial hypertension, glucose intolerance, dyslipidemia and obstructive sleep apnea. 5 Obesity is present in approximately 50%, 4 whereas insulin resistance occurs in 60% to 95% of them, 6 leading to glucose intolerance in 31% to 35% 7 and type 2 diabetes mellitus in 7.5% to 20% 8 of these women. However, dyslipidemia is the most common metabolic abnormality in PCOS, generally presenting with the phenotype exhibiting low levels of high-density lipoprotein (HDL) and high levels of triglycerides, consistent with insulin resistance, also presenting with increased insulin resistance and low-density lipoprotein (LDL) cholesterol levels. 7, 8 The prevalence of non-alcoholic fatty liver disease and obstructive sleep apnea are also high in women with PCOS. Even after controlling for body mass index (BMI), women with PCOS are still 30-fold more likely to have sleep-disordered breathing. 9, 10 Sub-clinical markers of cardiovascular disease, such as increased carotid artery intima-media thickness, 11 increased calcification of the coronary arteries, 12 and higher serum concentrations of C-reactive protein 13 have also been associated with PCOS.
There is evidence that the autonomic nervous system (ANS) plays an important role in ovarian physiology regulation.
14 It is estimated that increased sympathetic activity in women with PCOS may be associated with their hormonal and metabolic characteristics. 15 Although autonomic dysfunction is considered a predictor of cardiovascular events and mortality, 16 there is limited evidence of alterations in this pathophysiological parameter among women with PCOS.
A study showed that rats with estrogen-induced polycystic ovaries showed high uptake of norepinephrine, and a high degree of the neurotransmitter release with ovarian electrical stimulation. 17 Yildirir et al. analyzed heart rate variation (HRV) in women with PCOS, demonstrating a significant increase in the low-frequency spectrum component and a decrease in the high-frequency component in relation to the control group. 18 Tekin et al. showed a decrease in heart rate and blood pressure recovery after exertion in comparison to controls. 19 Drag et al. demonstrated dysfunction of the sympathetic and parasympathetic components of ANS in women with PCOS using electromyography. 20 The authors found no association between weight gain as measured by BMI and alterations in skin sympathetic response tests and R-R interval variation, parameter of the parasympathetic response, attributing to hyperandrogenism and insulin resistance the probable cause of the dysfunction. 20 Using the HRV spectral analysis, the study by Philbois SV et al., published in this issue of ABC Cardiol, found no alterations in autonomic cardiovascular control in women with PCOS. 1 However, the authors correlated the decline in baroreflex sensitivity, an important measure of autonomic cardiovascular function, as well as the attenuation of HRV values, with the increase of body fat in women with PCOS. 1 Although the results of the studies are conflicting, it can be concluded that insulin resistance, hyperandrogenism and obesity may result in autonomic dysfunction in PCOS. 1, [17] [18] [19] [20] [21] This autonomic dysregulation is recognized as a factor of worse prognosis, 16, 22 in addition to the set of metabolic [5] [6] [7] [8] clinical, 9,10 and structural alterations [11] [12] [13] related to the syndrome when determining a higher cardiovascular risk. Despite all these demonstrations of subclinical dysfunction, there is still a lack of conclusive, long-term follow-up studies in these women, aiming to demonstrate definitive evidence of increased cardiovascular clinical outcomes associated with PCOS. 23 
